Drug Trial Radar · NCT06565650
A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.
Last checked: Nov 20, 2026Latest source record: Dec 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
216
Actual
Start
Jul 31, 2024
Primary completion
Nov 2025
Study completion Nov 2025
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Aug 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Randomized, Multicenter, Double-Masked, Saline-Controlled Trial to Evaluate Corneal Endothelial Cell Density in Subjects With Dry Eye Disease Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months
Conditions
- Dry Eye
Interventions
MieboDrug
100% perfluorohexyloctane
SalineDrug
0.6% sodium chloride solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from baseline in ECDTime frame: Assessed at Month 3 and Month 12 Visits
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Site 101
Glendale, California
Site 112
Murrieta, California
Site 102
Newport Beach, California
Site 109
Rancho Cordova, California
Site 106
Torrance, California
Site 113
Delray Beach, Florida
Site 107
Morrow, Georgia
Site 105
Carmel, Indiana
Site 110
Kansas City, Missouri
Site 104
St Louis, Missouri
Site 108
Asheville, North Carolina
Site 103
Memphis, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.